Introduction: Urinary tract infections (UTIs) are among the most common infections both in the community and in the hospital setting.
Aim: The aim of this study is to investigate the etiological spectrum and antimicrobial resistance of most frequently isolated pathogens, associated with UTIs in ambulatory patients in Varna city, Bulgaria during a seven-month period (October 2020–April 2021).
Materials and Methods: A total of 1600 urine samples, collected from patients with suspected UTIs were tested. Screening for bacterial growth was done by HM&L Uroquattro instrument (ALIFAX, Italy). Species identification and antimicrobial susceptibility testing were performed by VITEK 2 Compact System (bioMerieux) and Kirby-Bauer disk diffusion method.
Results: E. coli was the most commonly isolated uropathogen regardless of the age group (48%, n = 61), followed by Enterococcus faecalis (33%, n = 42) and other representatives of order Enterobacterales (13.3%, n = 18). The resistance rates in the group of Gram-negative isolates (n = 79) in decreasing order were as follows: ampicillin, 64.5% > trimethoprim/sulfamethoxazole, 36% > ciprofloxacin, 29.1% > amoxicillin-clavulanic acid, 27.8% > cefuroxime, levofloxacin, 21.5% > fosfomycin, 13.1% > ceftriaxone, 12.6% > ceftazidime, 10.1% > gentamicin, nitrofurantoin, 6.5% > nitroxoline, 4.9%. The resistance rates among the isolates of E. faecalis (n = 42) were as follows: ciprofloxacin, 28.6% > gentamicin, 23.8% > levofloxacin, 19% > nitrofurantoin, 4.7% > amoxicillin, 2.4%. No resistance to meropenem, amikacin, vancomycin, and teicoplanin was found in the studied collection of isolates (n = 127).
Conclusion: The etiological spectrum of UTIs in ambulatory patients was dominated by E. coli, followed by E. faecalis. In the group of Gram-negative uropathogens, high resistance rates to ampicillin, trimethoprim/sulfamethoxazole and quinolones were detected. Third-generation cephalosporins, fosfomycin, nitrofurantoin and nitroxoline retained very good activity. Among Enterococcus faecalis isolates, the second most commonly isolated bacterial species, a decreased activity of quinolones was found too, but the aminopenicillins and nitrofurantoin remain highly active.
Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269-84. doi:10.1038/nrmicro3432.
Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000;10(8):509-19. doi: 10.1016/s1047-2797(00)00072-7.
Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004;2004(3):CD001209. doi: 10.1002/14651858.CD001209.pub2.
Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51-77. doi: 10.1093/cid/ciw118.
Surveillance of antimicrobial resistance in Bulgaria--a synopsis from BulSTAR 2018. Available at: https:// bam-bg.net//
Maki DG, Tambyah PA. Engineering out the risk for infection with urinary catheters. Emerg Infect Dis. 2001;7(2):342–7. doi: 10.3201/eid0702.010240.
Martínez-Casanova J, Gómez-Zorrilla S, Prim N, Dal Molin A, Echeverría-Esnal D, Gracia-Arnillas MP, et al. Risk factors for amoxicillin-clavulanate resistance in community-onset urinary tract infections caused by Escherichia coli or Klebsiella pneumoniae: the role of prior exposure to fluoroquinolones. Antibiotics (Basel). 2021;10(5):582. doi: 10.3390/antibiotics10050582.
Gaspari RJ, Dickson E, Karlowsky J, Doern G. Antibiotic resistance trends in paediatric uropathogens. Int J Antimicrob Agents. 2005;26(4):267-71. doi: 10.1016/j.ijantimicag.2005.07.009.
Pharmaceutical-therapeutic guideline for nephrology and dialysis. State Gazette. 2019;91. (in Bulgarian).
Marhova M, Kostadinova S, Stoitsova S. (2009) Antimicrobial resistance profiles of urinary Escherichia coli isolates. Biotechnol Biotechnol Equip. 2009;23(Suppl. 1):616-20. doi: 10.1080/13102818.2009.10818500.
Stefaniuk E, Suchocka U, Bosacka K, Hryniewicz W. Etiology and antibiotic susceptibility of bacterial pathogens responsible for community-acquired urinary tract infections in Poland. Eur J Clin Microbiol Infect Dis. 2016;35(8):1363-9. doi: 10.1007/s10096-016-2673-1.
Duicu C, Cozea I, Delean D, Aldea AA, Aldea C. Antibiotic resistance patterns of urinary tract pathogens in children from Central Romania. Exp Ther Med. 2021;22(1):748. doi:10.3892/etm.2021.10180.
Gul A, Gurbuz E. Microorganisms and antibiotic susceptibilities isolated from urine cultures. Arch Ital Urol Androl. 2020;92(2). doi: 10.4081/aiua.2020.2.146.
Mendelson G, Hait V, Ben-Israel J, Gronich D, Granot E, Raz R. Prevalence and risk factors of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in an Israeli long-term care facility. Eur J Clin Microbiol Infect Dis. 2005;24(1):17-22. doi: 10.1007/s10096-004-1264-8.
Gharavi MJ, Zarei J, Roshani-Asl P, Yazdanyar Z, Sharif M, Rashidi N. Comprehensive study of antimicrobial susceptibility pattern and extended spectrum beta-lactamase (ESBL) prevalence in bacteria isolated from urine samples. Sci Rep. 2021;11(1):578. doi:10.1038/s41598-020-79791-0.
Raphael E, Glymour MM, Chambers HF. Trends in prevalence of extended-spectrum beta-lactamase-producing Escherichia coli isolated from patients with community- and healthcare-associated bacteriuria: results from 2014 to 2020 in an urban safety-net healthcare system. Antimicrob Resist Infect Control. 2021;10(1):118. doi:10.1186/s13756-021-00983-y.
Chervet D, Lortholary O, Zahar JR, Dufougeray A, Pilmis B, Partouche H. Antimicrobial resistance in community-acquired urinary tract infections in Paris in 2015. Med Mal Infect. 2018;48(3):188-92. doi: 10.1016/j.medmal.2017.09.013..
Rupp ME, Fey PD. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs. 2003;63(4):353-65. doi: 10.2165/00003495-200363040-00002.
Chao YS, Farrah K. Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019.
Colgan R, Williams M. Diagnosis and treatment of acute uncomplicated cystitis. Am Fam Physician. 2011;84(7):771-6.
Wagenlehner F, Schmiemann G, editors. Epidemiology, diagnosis, treatment prevention and management of uncomplicated, bacterial, community-acquired urinary tract infections in adult patients. Langversion 1.1-2 AWMF-Register-Nr. 043/044. AWMF: Düsseldorf, Germany; 2017.
Email this article (Login required) 
